Abstract
Epigenetic abnormality is a hallmark of acute myeloid leukemia (AML), and aberrant 5-hydroxymethylcytosine (5hmC) levels are commonly observed in AML patients. As epigenetic subgroups of AML correlate with different clinical outcomes, we investigated whether plasma cell-free DNA (cfDNA) 5hmC could categorize AML patients into subtypes. We profiled the genome-wide landscape of 5hmC in plasma cfDNA from 54 AML patients. Using an unbiased clustering approach, we found that 5hmC levels in genomic regions with a histone mark H3K4me3 classified AML samples into three distinct clusters that were significantly associated with leukemia burden and survival. Cluster 3 showed the highest leukemia burden, the shortest overall survival of patients, and the lowest 5hmC levels in the TET2 promoter. 5hmC levels in the TET2 promoter could represent TET2 activity resulting from mutations in DNA demethylation genes and other factors. The novel genes and key signaling pathways associated with aberrant 5hmC patterns could add to our understanding of DNA hydroxymethylation and highlight the potential therapeutic targets in AML. Our results identify a novel 5hmC-based AML classification system and further underscore cfDNA 5hmC as a highly sensitive marker for AML.
Original language | English (US) |
---|---|
Article number | 1180 |
Journal | Genes |
Volume | 14 |
Issue number | 6 |
DOIs | |
State | Published - May 28 2023 |
Keywords
- 5-hydroxymethylcytosine
- acute myeloid leukemia
- cell-free DNA
- classification
- Proto-Oncogene Proteins/genetics
- Humans
- 5-Methylcytosine/metabolism
- Leukemia, Myeloid, Acute/genetics
ASJC Scopus subject areas
- Genetics(clinical)
- Genetics